ADIM
SRPT icon

Alpha DNA Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Alpha DNA Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,832
Closed -$562K – 246
2023
Q4 		$562K Buy
+5,832
New +$559K 0.22% 91
2022
Q1 		– Sell
-17,522
Closed -$1.58M – 152
2021
Q4 		$1.58M Buy
+17,522
New +$1.5M 1% 46

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Alpha DNA Investment Management's SRPT Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 5,832 shares — an estimated $562K sold.

Alpha DNA Investment Management first reported a position in SRPT in Q4 2021 and held it in 2 quarters. The position peaked at $1.58M in Q4 2021. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Alpha DNA Investment Management reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 5,832 Sarepta Therapeutics shares in Q1 2024, an estimated $562K.
  • Alpha DNA Investment Management first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 2 quarters.
  • Alpha DNA Investment Management's Sarepta Therapeutics position peaked at $1.58M in Q4 2021.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.